CalciMedica Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
36.9%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.66next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly8.2MTarget: Sufficient to fund operations into Q4 2026
Research and Development (R&D) Expenses Quarterly3.5M
General and Administrative (G&A) Expenses Quarterly2.1M
Watch Items
- FDA feedback on the design of the potential pivotal program for Auxora in acute pancreatitis (AP)Trigger: Receipt of official FDA feedback (expected in Q2 2026)Action: Finalize pivotal trial design and initiate the late-stage clinical program
- FDA feedback on potential future development of Auxora in acute kidney injury (AKI)Trigger: Receipt of official FDA feedback following the discontinuation of the Phase 2 KOURAGE trialAction: Evaluate next steps and potential trial redesigns for Auxora in AKI
- IND-enabling studies and preclinical progress for oral CRAC inhibitor CM5480Trigger: IND submission in pulmonary hypertension (expected in 2027)Action: Complete IND-enabling studies and file the IND application
- Nasdaq Listing Compliance (Minimum Bid Price and Market Value of Listed Securities)Trigger: Compliance deadlines in September 2026 (September 9, 2026 for MVLS and September 14, 2026 for Minimum Bid Price)Action: Regain compliance with Nasdaq's $1.00 minimum bid price and $35,000,000 MVLS requirements
Research as of 19 Jun 2026